Marcus-Hillert Schultze-Mosgau

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 10

Top Topics

Mycobacterium Tuberculosis

Randomized Controlled Trial

Cervical Cancer Screening

Top Venues

Clinical pharmacology and therapeutics

British journal of clinical pharmacology

European journal of drug metabolism and pharmacokinetics

Clinical pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Friederike Kanefendt, André Dallmann, Huijun Chen, Klaus Francke, Tianxing Liu, Christine Brase, Sebastian Frechen, Marcus-Hillert Schultze-Mosgau
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling. Clinical pharmacology and therapeutics 115 (5) (2024)
Friederike Kanefendt, André Dallmann, Huijun Chen, Klaus Francke, Tianxing Liu, Christine Brase, Sebastian Frechen, Marcus-Hillert Schultze-Mosgau
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling. Clinical pharmacology and therapeutics 115 (5) (2024)
Friederike Kanefendt, André Dallmann, Huijun Chen, Klaus Francke, Tianxing Liu, Christine Brase, Sebastian Frechen, Marcus-Hillert Schultze-Mosgau
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from Two Clinical DDI Studies and PBPK Modeling. Clinical pharmacology and therapeutics (2023)
Friederike Kanefendt, André Dallmann, Huijun Chen, Klaus Francke, Tianxing Liu, Christine Brase, Sebastian Frechen, Marcus-Hillert Schultze-Mosgau
Assessment of the CYP3A4 Induction Potential by Carbamazepine: Insights from two Clinical DDI Studies and PBPK Modeling. Clinical pharmacology and therapeutics (2023)
Gabriele Sutter, Matthias Frei, Marcus-Hillert Schultze-Mosgau, Kathrin Petersdorf, Christian Seitz, Bart A Ploeger
Assessment of the safe and efficacious dose of the selective progesterone receptor modulator vilaprisan for the treatment of patients with uterine fibroids by exposure-response modelling and simulation. British journal of clinical pharmacology (2021)
Marcus-Hillert Schultze-Mosgau, Bart A Ploeger, Matthias Frei, Joachim Höchel, Antje Rottmann
Clinical Pharmacokinetics and Pharmacodynamics of the Selective Progesterone Receptor Modulator Vilaprisan: A Comprehensive Overview. Clinical pharmacokinetics (2021)
Marcus-Hillert Schultze-Mosgau, Shunji Matsuki, Kazuhito Okumura, Masato Kaneko
Single- and Multiple-Dose Pharmacokinetics and Safety of Vilaprisan in Healthy Postmenopausal Japanese Women: A Randomized Clinical Trial. European journal of drug metabolism and pharmacokinetics (2021)
Marcus-Hillert Schultze-Mosgau, Barbara Schütt, Corinna Draeger, Manuela Casjens, Stephanie Loewen, Torsten Zimmermann, Beate Rohde
The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive-A randomized controlled trial. British journal of clinical pharmacology 87 (3) (2020)
Niladri Chattopadhyay, Kai Riecke, Sandra Ligges, Torsten Zimmermann, Atef Halabi, Marcus-Hillert Schultze-Mosgau
Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. British journal of clinical pharmacology 85 (9) (2019)
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, Sebastian Frechen, Sandra Ligges, Torsten Zimmermann, Antje Rottmann, Bart Ploeger, Joachim Höchel, Marcus-Hillert Schultze-Mosgau
CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans. British journal of clinical pharmacology 84 (12) (2018)